Poor
Major Nonconformance
Patient Risk:
High
Summary
Moderate agreement on mechanism/indications and some safety warnings, but many specific quantitative, OTC-specific, timing, and pregnancy claims are not supported by the provided label; one pregnancy-category claim is contradicted.
Category Scores
Accurate Statements
Esomeprazole (Nexium) is a proton pump inhibitor (PPI).
Supported by 12.1 Mechanism of Action (H+/K+ ATPase inhibition).
Esomeprazole reduces stomach acid production.
Supported by 12.1 Mechanism of Action (suppresses gastric acid secretion).
Esomeprazole blocks an enzyme in stomach cells responsible for acid secretion.
Supported by 12.1 Mechanism of Action (inhibition of H+/K+ ATPase at parietal cell surface).
For erosive esophagitis (EE) from GERD, patients take 20 to 40 mg daily for 4 to 8 weeks.
Supported by 1.1 Healing of Erosive Esophagitis and 2.1 Table 1 (20 mg or 40 mg once daily; 4 to 8 weeks).
Esomeprazole treats erosive esophagitis.
Supported by 1.1 Healing of Erosive Esophagitis.
Esomeprazole reduces risk of NSAID-associated gastric ulcers.
Supported by 1.4 Risk Reduction of NSAID-Associated Gastric Ulcer.
Esomeprazole treats Zollinger-Ellison syndrome (pathological hypersecretory conditions).
Supported by 1.6 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome.
Short-term side effects include headache, nausea, diarrhea, and flatulence.
Supported by 6.1 Clinical Trials Experience (adverse reactions at least 1% and includes headache; nausea/flatulence reported at similar rates).
Esomeprazole should be used at the lowest dose for the shortest time.
Supported by 5.3 and 5.4 (patients should use the lowest dose and shortest duration appropriate).
The typical use is once daily before meals.
Supported by 2.1 dosing frequency (once daily) and 2.3 instruction to take at least one hour before meals.
Esomeprazole is the S-isomer of omeprazole.
Supported by 8.1 Pregnancy section.
Esomeprazole should be avoided if allergic to PPIs (hypersensitivity to substituted benzimidazoles).
Supported by 4 Contraindications (known hypersensitivity to substituted benzimidazoles).
Unsupported Statements
Esomeprazole lowers acid levels by up to 90% within days.
No quantitative “up to 90% within days” statement in the provided label sections.
Esomeprazole treats frequent heartburn occurring two or more days a week.
No label support for this frequency-based claim in provided label sections.
OTC versions of esomeprazole handle uncomplicated heartburn for up to 14 days.
OTC-specific duration/indication claim not supported by provided label sections.
Symptom relief from esomeprazole starts within 1 to 4 days.
No label support for this specific timing claim in provided sections.
Full acid control with esomeprazole is achieved by day 5.
No label support for this exact “acid control by day 5” claim in provided sections.
Delayed-release suspension formulations of esomeprazole are available at strengths of 2.5 mg, 5 mg, 10 mg, and 20 mg.
Provided label section 3 lists only delayed-release oral suspension 10 mg packet strength; the additional strengths are not supported by provided text.
Delayed-release suspension is used for those who cannot swallow pills.
No provided label statement linking formulation choice to inability to swallow pills.
OTC Nexium 24HR (esomeprazole 20 mg) is taken as 1 capsule daily for a maximum of 14 days.
OTC dosing instruction not supported by provided label sections.
Prescription versions of esomeprazole last up to 3 months per course without doctor reevaluation.
No provided label support for “up to 3 months” course duration or “without doctor reevaluation.”
Esomeprazole may suppress acid slightly more effectively than omeprazole in some studies.
No provided label support for this specific comparative “slightly more effectively” framing.
Esomeprazole may have stronger acid suppression in CYP2C19 poor metabolizers.
No provided label support for this specific comparative effect statement.
Generics of esomeprazole are available since 2014.
Not an FDA label claim in provided sections.
The main composition patent for Nexium (U.S. 5,877,192) expired in 2014.
Patent/legal history not present in provided label sections.
Pediatric exclusivity for Nexium ended in May 2014.
Exclusivity timeline not present in provided label sections.
AstraZeneca faced challenges from Ranbaxy and others, settling lawsuits to delay some generics entries.
Not present in provided label sections.
Esomeprazole should be avoided with untreated Clostridium difficile.
No provided label statement instructing avoidance specifically for “untreated C. difficile.”
Tapering off after long-term use of esomeprazole is advised to prevent rebound acid.
No provided label support for tapering/rebound-acid guidance.
Contradictions
High
AI Statement
Esomeprazole is not recommended during pregnancy because it is pregnancy category C.
Label Reference
8.1 Pregnancy
Important Omissions
Safety Assessment
Potential Patient Risk:
High
A pregnancy categorization claim directly contradicts the provided label content and may mislead use in pregnancy. Multiple unsupported OTC/dosing/timing claims could also lead to inaccurate use instructions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Major Nonconformance
Primary Issue
Contradicted pregnancy category guidance plus numerous unsupported quantitative/OTC/timing instructions.
Suggested Improvement
Restrict statements to the provided label text (mechanism, indicated uses, specific labeled dosing/durations, and labeled warnings/precautions) and remove unsupported OTC/legal/quantiative timing and course-duration claims.